Welcome to the new Hypertrophic Cardiomyopathy (HCM) Knowledge Hub powered by CardioNerds. Each week we’ll deliver key insights and unique perspectives through podcasts, articles, infographics, videos, and more—all uniquely created by cardiologists to inform and educate.

Featured Podcast

84. Case Report: Hypertrophic Cardiomyopathy with Superimposed Stress Cardiomyopathy – Brown University

CardioNerds (Amit Goyal & Daniel Ambinder) join Brown University cardiology fellows (Greg Salber, Vrinda Trivedi, and Esseim Sharma) for a gorgeous coastal boat ride in Providence, RI. They discuss an educational case of hypertrophic cardiomyopathy wit...

68. Case Report: WPW and HCM Phenotype – VCU

CardioNerds (Amit Goyal & Daniel Ambinder) join Virginia Commonwealth University (VCU) cardiology fellows (Ajay Pillai, Amar Doshi, and Anna Tomdio) for a delicious skillet breakfast and amazing day in Richmond, VA!

6. Hypertrophic Cardiomyopathy Surgical & Transcatheter Septal Reduction Therapies with Drs. Amar Krishnaswamy and Per Wierup

Obstructive hypertrophic cardiomyopathy therapy and septal reduction therapy via alcohol septal ablation and surgical myectomy is discussed by interventional cardiologist Dr. Amar Krishnaswamy and surgical perspective from cardiothoracic surgeon Dr. Per Wierup. Amit joins Dr. Laura Young to take a pulse check with...

5. Hypertrophic Cardiomyopathy Historical Perspective with Dr. Edward Kasper

Dr. Edward Kasper shares a unique historical perspective on how the field evolved as medicine learned more about HCM. He shares so many life lessons and clinical pearls that apply to HCM and the practice of medicine in general. Flutter moment by Dr.

4. Practical Approach to HCM with Dr. Jose Madrazo

Clinical and echo expert Dr. Jose Madrazo discusses a high yield and practical approach to diagnosis and management of hypertrophic cardiomyopathy.

3. Hypertrophic Cardiomyopathy: Case Discussion

Dr. Fatimah Alkhunaizi and the CardioNerds discuss a case of hypertrophic cardiomyopathy, covering pathophysiology, diagnosis, imaging, and management of HCM.  

166. CardioNerds Rounds: Challenging Cases of Hypertrophic Cardiomyopathy with Dr. Michelle Kittleson

CardioNerds Rounds Co-Chair, Dr. Karan Desai, joins Dr. Michelle Kittleson (Director of Postgraduate Education in Heart Failure and Transplantation, Director of Heart Failure Research, and Professor of Medicine at the Smidt Heart Institute at Cedars-Si...

Podcast 118. The Braunwald Chronicles: A “Royal Screw-up” & The Discovery of Hypertrophic Cardiomyopathy

CardioNerds (Amit Goyal, Daniel Ambinder, Carine Hamo, and Karan Desai) are honored to bring to you the Braunwald Chronicles. These are stories of discovery, innovation, accidents, perseverance, and more…truly these are the stories of cardiology,

Featured News

TRIAL SUMMARY: VALOR-HCM

Mavacamten in adults with symptomatic obstructive HCM who are eligible for septal reduction therapy (VALOR-HCM) Milind Y. Desai, Kathy Wolski, Anjali Owens, Srihari S. Naidu,...

117. The Braunwald Chronicles: Natural History of Aortic Stenosis, Beta-Blockers in Heart Failure &...

CardioNerds (Amit Goyal, Daniel Ambinder, Carine Hamo, and Karan Desai) are honored to bring to you the Braunwald Chronicles. These are stories of discovery, innovation, accidents, perseverance, and more…truly these are the stories of cardiology,

TRIAL SUMMARY: EXPLORER-HCM

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM) Iacopo Olivotto, Artur Oreziak, Roberto Barriales-Villa, Theodore P Abraham, Ahmad Masri, Pablo Garcia-Pavia, Sara Saberi, Neal...

The Digital Diagnostician: Deep Learning to Detect HCM vs. Amyloidosis

As novel therapeutic agents such as Mavacamten and Tafamidis are developed and become clinically useful for patients with hypertrophic cardiomyopathy (HCM) and cardiac amyloidosis...
VALOR-HCM: Mavacamten Decreases Need for Septal Reduction Therapy in Symptomatic Obstructive HCM

VALOR-HCM: Mavacamten Decreases Need for Septal Reduction Therapy in Symptomatic Obstructive HCM

New pharmacological agent reduces need for septal reduction therapy in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), according to new trial discussed at the...

Spotlight: Video

The VALOR-HCM Trial: Encouraging Findings for Patients with Obstructive HCM

In this insightful interview, Dr. Rawan Amir speaks with Dr. Milind Desai, director of the Center for Hypertrophic Cardiomyopathy and medical director of the Center of Aortic Diseases, Cleveland Clinic, about the phase III VALOR-HCM trial, which assessed mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy.

The CardioNerds Discuss their Mission, their Partnership with DocWire News, and Future Plans
We sat down with Amit Goyal, MD, and Daniel Ambinder, MD, Cofounders of CardioNerds, who discussed the genesis of the platform, its mission, future plans, and, of course, the partnership with DocWire.

Hypertrophic Obstructive Cardiomyopathy
A middle-aged woman with hypertrophic cardiomyopathy now presents with progressive exertional shortness of breath. See how this plays out…

Spotlight: Infographic

Pathophysiology of HCM vs. Treatment with Mavacamten

Many CCU patients have Swan-Ganz/PA catheters in place. They provide extremely valuable diagnostic and prognostic information and can be a critical tool for guiding management in critically ill patients. However, the sheer amount of data can sometimes be overwhelming. This infographic aims to help with learning the normal intracardiac pressures; utilization of these variables to derive important hemodynamic parameters; and understanding the diagnostic and/or prognostic significance of these parameters, including how to use them in clinical practice.

References:

“PVR is the recommended parameter for differentiating subtypes of PH.”
Galiè N, McLaughlin VV, Rubin LJ, Simonneau G. An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J. 2019 Jan 24;53(1):1802148. doi: 10.1183/13993003.02148-2018. PMID: 30552088; PMCID: PMC6351332.


“PAPi ≤ 0.9 predicts RV failure and in-hospital mortality in inferior MI.”
Korabathina R, Heffernan KS, Paruchuri V, Patel AR, Mudd JO, Prutkin JM, Orr NM, Weintraub A, Kimmelstiel CD, Kapur NK. The pulmonary artery pulsatility index identifies severe right ventricular dysfunction in acute inferior myocardial infarction. Catheter Cardiovasc Interv. 2012 Oct 1;80(4):593-600. doi: 10.1002/ccd.23309. Epub 2012 Jan 10. PMID: 21954053.


“PAPi < 1.85 predicts RV failure in patients with LVADs.”
Morine KJ, Kiernan MS, Pham DT, Paruchuri V, Denofrio D, Kapur NK. Pulmonary Artery Pulsatility Index Is Associated With Right Ventricular Failure After Left Ventricular Assist Device Surgery. J Card Fail. 2016 Feb;22(2):110-6. doi: 10.1016/j.cardfail.2015.10.019. Epub 2015 Nov 10. PMID: 26564619.


“RA/PCWP > 0.54 predicted RV dysfunction in patients with LVADs.”
Soliman OII, Akin S, Muslem R, Boersma E, Manintveld OC, Krabatsch T, Gummert JF, de By TMMH, Bogers AJJC, Zijlstra F, Mohacsi P, Caliskan K; EUROMACS Investigators. Derivation and Validation of a Novel Right-Sided Heart Failure Model After Implantation of Continuous Flow Left Ventricular Assist Devices: The EUROMACS (European Registry for Patients with Mechanical Circulatory Support) Right-Sided Heart Failure Risk Score. Circulation. 2018 Feb 27;137(9):891-906. doi: 10.1161/CIRCULATIONAHA.117.030543. Epub 2017 Aug 27. PMID: 28847897.


“RA/PCWP >0.63 predicted RV dysfunction in patients with LVADs.”
Kormos RL, Teuteberg JJ, Pagani FD, Russell SD, John R, Miller LW, Massey T, Milano CA, Moazami N, Sundareswaran KS, Farrar DJ; HeartMate II Clinical Investigators. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. J Thorac Cardiovasc Surg. 2010 May;139(5):1316-24. doi: 10.1016/j.jtcvs.2009.11.020. Epub 2010 Feb 4. PMID: 20132950.


“CPO of <0.6 was the strongest independent hemodynamic correlate in the SHOCK trial registry for in-hospital mortality in patients with cardiogenic shock.”
Fincke R, Hochman JS, Lowe AM, Menon V, Slater JN, Webb JG, LeJemtel TH, Cotter G; SHOCK Investigators. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol. 2004 Jul 21;44(2):340-8. doi: 10.1016/j.jacc.2004.03.060. PMID: 15261929.


“LV Transmural Filling Pressure.”
Borlaug BA, Reddy YNV. The Role of the Pericardium in Heart Failure: Implications for Pathophysiology and Treatment. JACC Heart Fail. 2019 Jul;7(7):574-585. doi: 10.1016/j.jchf.2019.03.021. PMID: 31248569; PMCID: PMC6601642.


“Studies have shown good correlation between TD and Direct Fick in severe TR and extremes of CO.”
Hoeper MM, Maier R, Tongers J, Niedermeyer J, Hohlfeld JM, Hamm M, Fabel H. Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med. 1999 Aug;160(2):535-41. doi: 10.1164/ajrccm.160.2.9811062. PMID: 10430725.


“Central venous pressure (CVP) was shown as one of the predictors of SCAI profile and mortality in the Cardiogenic Shock Working Group registry.” Thayer KL, Zweck E, Ayouty M, Garan AR, Hernandez-Montfort J, Mahr C, Morine KJ, Newman S, Jorde L, Haywood JL, Harwani NM, Esposito ML, Davila CD, Wencker D, Sinha SS, Vorovich E, Abraham J, O’Neill W, Udelson J, Burkhoff D, Kapur NK. Invasive Hemodynamic Assessment and Classification of In-Hospital Mortality Risk Among Patients With Cardiogenic Shock. Circ Heart Fail. 2020 Sep;13(9):e007099. doi: 10.1161/CIRCHEARTFAILURE.120.007099. Epub 2020 Sep 9. PMID: 32900234.

Yung GL, Fedullo PF, Kinninger K, Johnson W, Channick RN. Comparison of impedance cardiography to direct Fick and thermodilution cardiac output determination in pulmonary arterial hypertension. Congest Heart Fail. 2004 Mar-Apr;10(2 Suppl 2):7-10. doi: 10.1111/j.1527-5299.2004.03406.x. PMID: 15073478.

“Central venous pressure (CVP) was shown as one of the predictors of SCAI profile and mortality in the Cardiogenic Shock Working Group registry.”
Thayer KL, Zweck E, Ayouty M, Garan AR, Hernandez-Montfort J, Mahr C, Morine KJ, Newman S, Jorde L, Haywood JL, Harwani NM, Esposito ML, Davila CD, Wencker D, Sinha SS, Vorovich E, Abraham J, O’Neill W, Udelson J, Burkhoff D, Kapur NK. Invasive Hemodynamic Assessment and Classification of In-Hospital Mortality Risk Among Patients With Cardiogenic Shock. Circ Heart Fail. 2020 Sep;13(9):e007099. doi: 10.1161/CIRCHEARTFAILURE.120.007099. Epub 2020 Sep 9. PMID: 32900234.


Eric L. Bonno, Michael C. Viray, Gregory R. Jackson, Brian A. Houston, Ryan J. Tedford; Modern Right Heart Catheterization: Beyond Simple Hemodynamics. Advances in Pulmonary Hypertension 1 January 2020; 19 (1): 6–15.

Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. Tenth edition. Philadelphia, PA: Elsevier/Saunders, 2015.

Anwaruddin S, Martin JM, Stephens JC, Askari AT. Cardiovascular Hemodynamics: An Introductory Guide: Humana Press; 2012

This schematics and figures chart details the cascade of cardiovascular events which can lead to the development of hypertrophic cardiomyopathy (HCM). It also delineates the typical clinical manifestations, EKG and Echo findings association with HCM, and depicts the “4 P’s of Prevention”; outlining how to reduce the risk of four serious complications correlated with HCM.

Meet The NERDS!

Advertisement
Advertisement

More from CardioNerds